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AbstractA collection of 1159 enterococcal isolates from ﬁve Chinese
hospitals were screened for the presence of the novel
oxazolidinone resistance gene optrA, which was found in 34
(2.9%) isolates. Pulsed-ﬁeld gel electrophoresis (PFGE) typing of
29 optrA-carrying Enterococcus faecalis isolates revealed 25 PFGE
patterns, and multilocus sequence typing yielded 20 sequence
types. Routine surveillance of optrA-positive enterococci in
hospitals should be conducted to monitor and counteract their
further dissemination. The data of this study may be used as a
baseline from which to judge future decreases or increases in
optrA-positive enterococci.
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infections caused by vancomycin-resistant enterococci and
methicillin-resistant Staphylococcus aureus, oxazolidinones have
shown potent activity against most Gram-positive pathogens
[1,2]. Mutations or modiﬁcations of the target site within the
peptidyl transferase centre of the 50S ribosomal subunit can
result in resistance to oxazolidinones. Alterations in domain V
of the 23S rRNA, most frequently seen as a G2576T mutation,
constitute the main oxazolidinone resistance mechanism in
enterococci [3,4]. In addition, acquisition of the cfr gene, which
encodes a methyltransferase that modiﬁes the adenine at po-
sition 2503 in the peptidyl transferase centre and thereby
confers combined resistance to oxazolidinones, phenicols, lin-
cosamides, pleuromutilins, and streptogramin A antibiotics, has
been detected in enterococci and other Gram-positive and
Gram-negative bacteria [5,6].
Recently, the new oxazolidinone resistance gene optrA has
been identiﬁed in Enterococcus faecalis and Enterococcus faecium
isolates of human and animal origin [7]. This gene codes for an
ATP-binding cassette transporter that results in resistance or
elevated MICs for oxazolidinones (linezolid and tedizolid) and
phenicols (chloramphenicol and ﬂorfenicol), and was found in
2.0% (12/595) of the tested clinical E. faecalis and E. faecium
isolates collected from the Second Afﬁliated Hospital of Zhe-
jiang University, during 1998–2014 in Hangzhou, China [7].
However, the exact mechanism by which this ATP-binding
cassette transporter confers resistance to oxazolidinones and
phenicols is not fully understood, as it lacks a membrane
component. The optrA gene is the ﬁrst identiﬁed transferable
gene that results in an elevated MIC for tedizolid, a recently
approved novel oxazolidinone with improved activity against
linezolid-resistant isolates carrying cfr [8,9]. The emergence of
optrA in clinical enterococci is of great concern, as the spread of
this gene could signiﬁcantly limit the treatment options for
vancomycin-resistant enterococci. To obtain a better under-
standing of the presence of optrA in enterococci of human
clinical origin, we screened enterococci derived from hospi-
talized patients in China for the presence of optrA, and also
investigated the molecular epidemiology of optrA-carrying
isolates.
A total of 1159 non-duplicate enterococcal isolates were
randomly collected from ﬁve hospitals in ﬁve different cities of
China from 2010 to 2014 (Table S1). These isolates are
different from the enterococcal isolates previously reported
[7]. Species identiﬁcation was performed with matrix-assisted
laser desorption ionization time-of-ﬂight mass spectrometry
(Bruker Daltonik, Bremen, Germany). Isolates were obtained
from urine (62.9%), body ﬂuid (20.5%, including hydrothorax,
ascites, bile, cerebrospinal ﬂuid, and prostate ﬂuid), secretionsClin Microbiol Infect 2015; 21: 1095.e1–1095.e4




























FIG. 1. Year-by-year comparison of the presence of optrA-positive
enterococcal isolates.
1095.e2 Clinical Microbiology and Infection, Volume 21 Number 12, December 2015 CMI(11.1%, including pus, wound secretions, and secretions or
drainage of operation incision), and blood (5.5%). Urology
wards were the most common sources of samples (29.4%),
followed by hepatopancreatobiliary surgery wards (15.4%) and
intensive-care units (8.2%). Colonizing enterococcal isolatesTABLE 1. Clinical characteristics and molecular typing of 34 optrA
Isolate Hospital Year Sample Sex Age (years) Ward
Enterococcus faecalis
SR12140 A 2012 Prostate ﬂuid M 53 Urology
SR12155 A 2012 Urine M 41 Urology
SR12179 A 2012 Urine M 86 Vasculocardi
SR12188 A 2012 Urine F 29 Urology
SR12205 A 2012 Urine F 51 Urology
SR12219 A 2012 Wound secretion M 29 Hand surgery
SR136 A 2013 Blood F 71 Haematology
SR139 A 2013 Urine M 75 Urology
SR1311 A 2013 Urine M 81 Urology
SR1341 A 2013 Urine M 79 ICU
SR1382 A 2013 Ascites M 71 Anorectal
SR13118 A 2013 Urine M 84 Vasculocardi
SR13158 A 2013 Urine M 83 Urology
SR13179 A 2013 Urine F 66 Urology
SR13213 A 2013 Urine F 39 Urology
SR13217 A 2013 Urine M 86 Vasculocardi
SR13293 A 2013 Urine F 24 Urology
TZ32 B 2014 Bile M 73 Gastroentero
TZ145 B 2014 Urine F 54 Gynaecology
TZ147 B 2014 Urine F 20 Urology
TZ207 B 2014 Wound secretion M 93 Burn
CX81 C 2013 Blood M 58 Hepatopancr
CX84 C 2013 Wound secretion F 63 Orthopaedic
GZ6 D 2010 Urine M 56 Urology
ZZ12 E 2014 Urine M 79 Urology
ZZ31 E 2014 Urine M 56 Urology
ZZ36 E 2014 Wound secretion F 22 Gynaecology
ZZ129 E 2014 Ascites F 59 Hepatopancr
ZZ133 E 2014 Wound secretion F 50 Gynaecology
Enterococcus faecium
TZ199 B 2014 Wound secretion M 66 Orthopaedic
GZ124 D 2010 Urine F 48 Urology
GZ129 D 2011 Wound secretion F 45 Gastrointesti
Enterococcus thailandicus
TZ198 B 2014 Bile M 74 Hepatopancr
Enterococcus gallinarum
TZ208 B 2014 Ascites M 40 Hepatopancr
CC, clonal complex; F, female; ICU, intensive-care unit; LZD, linezolid; M, male; MLST, mul
aDD, Tyr176Asp/Gly393Asp; EDD, Lys3Glu/Tyr176Asp/Gly393Asp; EDM, Lys3Glu/Tyr176A
Tyr176Asp/Asp247Asn/Gly393Asp/Ile622Met; KD, Thr112Lys/Tyr176Asp; DP, Tyr176Asp/T
bST655, ST656, ST657, ST658 and ST659 were novel STs identiﬁed in this study.
cNone means that the ST could not be attributed to one of the recognized CCs.
Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infectfrom faecal or anal/rectal samples were not included in this
study.
All enterococcal isolates were inoculated on Columbia agar
plates (containing 5% v/v sheep blood) supplemented with
10 mg/L ﬂorfenicol, as the two transferable oxazolidinone
resistance genes known to date, optrA and cfr [6,7], also confer
resistance to chloramphenicol and ﬂorfenicol. Isolates growing
on the selective medium were screened for the presence of 23S
rRNA mutations, optrA and cfr, and the phenicol exporter genes
fexA and fexB, with speciﬁc PCR assays and sequence analysis of
the corresponding amplicons [7]. For optrA-positive isolates,
MICs were determined by broth microdilution according to the
recommendations of the CLSI [10,11]. Molecular typing was
performed by analysis of pulsed-ﬁeld gel electrophoresis
(PFGE) proﬁles of SmaI-digested chromosomal DNA [12] and
multilocus sequence typing, as described previously [13,14].
Among the 1159 enterococcal isolates tested, 38 (3.3%)
grew on ﬂorfenicol-supplemented medium, and 34 of 38
(89.5%) were positive for optrA (Table S1). Thirty-two of the 34
optrA-positive isolates also carried the phenicol resistance genes
fexA and/or fexB. The remaining four ﬂorfenicol-resistant but-positive enterococcal isolates
optrA varianta LZD MIC (mg/L) PFGE MLSTb CCc
RDK 8 A ST207 CC28
DP 4 B ST632 CC96
ology DP 4 C1 ST476 CC476
DP 4 D ST49 CC49
EDM 8 E ST59 CC59
W 8 C2 ST476 CC476
W 4 F ST655 None
W 4 F ST655 None
W 4 G ST619 CC81
W 8 H ST81 CC81
EDD 4 I ST192 None
ology KD 8 J1 ST16 CC16
W 8 L ST585 CC4
KD 8 J2 ST16 CC16
DP 4 K ST16 CC16
ology DP 8 M ST480 None
DP 8 N ST480 None
logy EYDNDM 2 O ST368 None
KD 8 P ST16 CC16
W 4 Q ST656 None
RDK 8 R ST314 CC314
eatobiliary EDM 2 S ST657 CC93
s EDM 2 S ST657 CC93
EYDNDM 2 T ST593 None
W 8 U ST658 CC476
DP 4 V ST659 None
EDP 4 W ST480 None
eatobiliary EDM 2 X ST591 CC16
EYDNDM 2 Y ST593 None
s EDM 4 — ST97 CC17
DD 4 — ST882 CC17
nal surgery DD 4 — ST885 CC17
eatobiliary EDM 2 — — —
eatobiliary EDD 2 — — —
tilocus sequence typing; PFGE, pulsed-ﬁeld gel electrophoresis; ST, sequence type.
sp/Ile622Met; EDP, Lys3Glu/Tyr176Asp/Thr481Pro; EYDNDM, Lys3Glu/Asn12Tyr/
hr481Pro; RDK, Ile104Arg/Tyr176Asp/Glu256Lys; W, wild type.
ious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 1095.e1–1095.e4
CMI Cai et al. optrA-carrying enterococci in Chinese hospitals 1095.e3optrA-negative isolates carried only fexB (three E. faecium) or
fexA (one E. faecalis). The 34 optrA-positive isolates comprised
29 E. faecalis, three E. faecium, and, for the ﬁrst time, single
isolates of Enterococcus gallinarum and Enterococcus thailandicus.
Neither 23S rRNA mutations nor cfr were detected in any of
these 34 isolates. In addition, no optrA was detected in 458
randomly chosen enterococcal isolates that failed to grow on
ﬂorfenicol-supplemented plates. Half of the patients from
whom optrA-positive isolates had been obtained had a history of
treatment with cephalosporins, and only two patients had
received previous linezolid treatment. A year-by-year com-
parison of optrA-positive isolates revealed a slight increase from
two (2.2%) and one (1.0%) isolates in 2010 and 2011, respec-
tively to 13 (2.9%) and 12 (4.1%) isolates in 2013 and 2014,
respectively (Fig. 1).
All optrA-positive isolates were susceptible to vancomycin
and daptomycin. Moreover, all 29 optrA-positive E. faecalis
isolates were susceptible to penicillin and ampicillin, but 17
(58.6%) of them were ciproﬂoxacin-resistant. Twenty-six
optrA-positive isolates were resistant or intermediately resis-
tant to linezolid, with MICs of 4–8 mg/L, whereas the
remaining eight isolates were borderline susceptible to line-
zolid (MIC of 2 mg/L). The corresponding elevated tedizolid
MICs for 28 of 34 (82.4%) of isolates ranged from 1 mg/L to
2 mg/L (Table S2), as compared with the previously tested
clinical isolates, with MIC50 and MIC90 values of 0.5 mg/L
[15]. Comparison of the deduced OptrA amino acid sequences
of the 34 isolates with that of the original OptrA from
E. faecalis E349 (designated as the wild type) revealed nine
variants. Among the eight linezolid borderline-susceptible iso-
lates, alterations at positions 3 (Lys3Glu), 12 (Asn12Tyr), 176
(Tyr176Asp), 247 (Asp247Asn), 393 (Gly393Asp), and 622
(Ile622Met) (EYDNDM variant) were identiﬁed in four isolates,
and alterations at positions 3 (Lys3Glu), 176 (Tyr176Asp) and
622 (Ile622Met) (EDM variant) were identiﬁed in three isolates
(Table 1). Whether any of these amino acid substitutions—
and, if so, which—account for the lower linezolid MICs is the
subject of a separate study.
PFGE and multilocus sequence typing analysis revealed that
the 29 optrA-positive E. faecalis isolates represented 25 PFGE
patterns and 20 sequence types (Table 1). However, occasional
clonal dissemination could be conﬁrmed in the same hospital;
for eaxmple, isolates SR136 and CX81 were indistinguishable
from isolates SR139 and CX84, respectively. Isolates with
similar PFGE patterns (difference of two to three bands) and
identical multilocus STs were observed, e.g. isolates SR12179
and SR12219, and isolates SR13118 and SR13179, respectively
(Fig. S1).
Owing to the important role of oxazolidinones as thera-
peutics in life-threatening infections caused by Gram-positiveClinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infebacteria, it is essential to screen enterococci and staphylo-
cocci for the presence of oxazolidinone resistance. The
occurrence of the novel transferable linezolid resistance gene
optrA, which also results in elevated MICs for tedizolid, is
alarming. Because of their low linezolid MICs of 4–8 mg/L—
and taking into account that, occasionally, isolates with an MIC
of 2 mg/L are also optrA-positive—such enterococci might be
easily overlooked in the clinical microbiology laboratory. As
optrA also confers phenicol resistance to enterococci and
staphylococci, ﬂorfenicol, which is exclusively approved for
food-producing animals, can be used in the initial screening,
followed by PCR analysis with optrA-speciﬁc primers [7].
Routine surveillance of optrA-carrying enterococcal clinical
isolates—supported by the molecular analysis of such iso-
lates—should be conducted to monitor, trace back and
counteract the further dissemination of optrA.Transparency declarationThe authors declare no conﬂicts of interest.AcknowledgementsThis work was funded by grants from the National Basic
Research Programme of China (grant 2013CB127200), the Na-
tional Natural Science Foundation of China (grant 31370046),
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